Cite
HARVARD Citation
Keeping, S. et al. (2018). Pembrolizumab versus the standard of care for relapsed and refractory classical Hodgkin's lymphoma progressing after brentuximab vedotin: an indirect treatment comparison. Expert review of hematology. 11 (6), pp. 503-511. [Online].